1. Academic Validation
  2. ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer

ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer

  • J Immunother Cancer. 2021 Jul;9(7):e001758. doi: 10.1136/jitc-2020-001758.
Zongren Wang  # 1 2 Xueling Zhang  # 1 Wuguo Li  # 3 Qiao Su 3 Zhaoyang Huang 1 Xinyao Zhang 1 2 Haiqi Chen 1 Chengqiang Mo 2 Bin Huang 2 Wei Ou 2 Junxing Chen 2 Guangyin Zhao 3 Lingwu Chen 4 Lan Shao 5
Affiliations

Affiliations

  • 1 The Center for Translational Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • 2 Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • 3 Animal Experiment Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • 4 Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China shaolan@mail.sysu.edu.cn chenlwu@mail.sysu.edu.cn.
  • 5 The Center for Translational Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China shaolan@mail.sysu.edu.cn chenlwu@mail.sysu.edu.cn.
  • # Contributed equally.
Abstract

Background: The efficacy of docetaxel-based chemotherapy is limited by the development of drug resistance. Recent studies demonstrated the efficacy of anti-programmed death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) immunotherapies in metastatic prostate Cancer. The ataxia telangiectasia mutation (ATM) protein plays a crucial role in maintaining genome stability and function of mitosis. Here, we aimed to determine whether PD-1/PD-L1 signaling contributes to the resistance to DTX and to elucidate the mechanism underlying DTX-induced PD-L1 expression.

Methods: In this retrospective study, PD-L1 expression was analyzed in 33 tumor tissue samples from prostate Cancer patients. Prostate cell lines were used to perform functional assays and examine underlying mechanisms in vitro. A fully mouse prostate Cancer model and a humanized chimeric mouse bearing human prostate tumors and peripheral blood mononuclear cells were used for in vivo assays.

Results: We have shown that DTX, a chemotherapeutic drug which causing microtubule interference, could significantly induce the expression of PD-L1 in prostate Cancer cells. This effect is blocked by the inhibition of ATM, suggesting that it plays an essential role in PD-L1 expression upregulated by DTX. Mechanistic studies have shown that ATM activity in Cancer cells enhances the stability of the NF-κB essential modulator (NEMO), which leading to an increase in the NF-κB activity and PD-L1 expression. Using the mouse model, it was further demonstrated that a combination of ATM and NEMO inhibitors along with DTX augmented the antitumor efficacy of chemotherapy, which are comparable to that of PD-L1 antibody.

Conclusions: Our findings have revealed that a previously unrecognized ATM-NEMO signaling which induced by DTX is capable of suppressing tumor immunity by activating the expression of PD-L1, suggesting that the ATM-NEMO-NF-κB axis can be exploited to restore the immune balance and overcome Cancer resistance triggered by DTX.Graphic Abstract: supplementary file 1.

Keywords

combination; drug therapy; immune evation; immunotherapy; programmed cell death 1 receptor.

Figures
Products